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Return to Play Guidelines: Infectious Mononucleosis
• Infectious mono incidence rate among young adults = 1-3%
• Incubation period = 30-50 days
• Symptoms typically begin as fever, malaise, and headache
▫ Pharyngitis develops in 80% of those affected 
▫ Splenomegaly occurs in 50-100%
• Characteristic exam findings:
▫ Posterior cervical lymphadenopathy
▫ Tonsillar enlargement or exudate
▫ Palatal petechiae
▫ Splenic enlargement
Infectious Mono + Athletics
• Rare complication: occurs in 0.1 – 0.2% of cases 
• Can occur spontaneously, or as a result of Valsalva or trauma
• Most cases occur in the first three weeks of illness
▫ Cases of splenic rupture have been reported up to 7 weeks following disease 
onset 
• Myths and misconceptions
▫ Splenic ultrasound has not been validated to be helpful in the assessment of 
splenomegaly 
 In a study of baseline splenic size in 631 healthy athletes, 7% met the criteria for 
splenomegaly
▫ Physical exam is unhelpful in determining splenic size 
 Combined palpation and percussion to assess splenomegaly has sensitivity of 46% and 
specificity of 97%
Splenic Rupture 
• Splenic rupture is due to trauma in 86% of cases 
▫ 14% occur spontaneously 




 85% of Burkitt lymphomas in Africa are EBV positive 
▫ Hodgkin lymphoma
 40% in developed countries and 80% in developing countries are EBV positive 
Public Health Costs
• On return to play implementation: 
“I follow the following framework. I keep people out of all athletic activities for 
three weeks from the onset of symptoms. To determine the onset of symptoms 
I take a careful history to figure out when they started feeling poorly. If there is 
ambiguity, I err on the more cautious date of onset. After three weeks I allow 
individuals to return to noncontact sports activities. I hold off on adding contact 
sports and higher level resistance training until the four-week mark. At four 




• On the ambiguity of date of onset, and the challenges of convincing 
patients who may already have resumed athletic participation when it 
was not safe to do so:





• Family physicians are often the first to evaluate athletes with suspected 
infectious mono, thus clear, universal guidelines for determining return to 
play are essential 
• Intervention: develop pictorial representation of current return to play 
guidelines for athletes with infectious mono
▫ Highlight indications for preventing return to play
▫ Acknowledge areas of ambiguity in diagnosis
▫ Provide evidence-based recommendations to help prevent unnecessary testing 
• Ensure dissemination of information to both physicians and coaches to avoid 
premature return to play 
▫ Due to delay in diagnosis, including description of signs and symptoms of 
infectious mono ensures athletes do not resume activities with possible 
splenomegaly 
Intervention and Methodology
• Staged diagram indicating parameters 
to be met for progressive return to play
▫ List of symptoms of infectious mono 
such that if an athlete presents with 
these consideration should be given to 
restricting play
▫ Suggestions for decision making when 
actual timing of infection onset is 
unclear 
• Description of symptoms of splenic 
rupture indicating immediate 
emergency evaluation
Results
• Main benefit is in saving provider time
▫ Consolidating the information and making it more accessible saves the provider 
an extensive literature search
▫ Incidence of splenic rupture is so low that rupture itself would not be an effective 
outcome to measure 
• Diagnostic ambiguity regarding date of onset of illness will persist, but trend 
toward assuming shorter length of infection will protect athletes given peak 
of splenomegaly occurs ~3 weeks post-infection 
• Predicted increased patient satisfaction if criteria for return to play is made 
clear from onset
▫ Athlete may still be playing sport at time of diagnosis, thus having clear 
framework in place can prevent distress over taking leave of absence from activity 
Evaluation and Effectiveness of Limitations
• Serial ultrasounds to measure arc of change of athletes’ spleens during mono 
infection 
▫ While studies estimate splenomegaly develops in 50-100% of cases of infectious 
mono, none have looked at the degree of change from baseline spleen size and 
time course of regression
▫ Current recommendations advise against splenic imaging due to lack of baseline 
against which to compare
▫ This information would be helpful in providing a more accurate window of time in 
which contact sports should be absolutely avoided
• Development of EBV vaccine 
▫ Current efforts have been focusing on gp350, which is highly conserved among 
EBV strains
▫ EBV infection linked to development of nasopharyngeal carcinoma and Hodgkin 
lymphoma, thus a vaccine preventing these outcomes is highly desirable
Recommendations for Future Interventions
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